Bosentan
Bosentan, sold as Tracleer, is an endothelin receptor antagonist. The US label lists treating pulmonary arterial hypertension (WHO Group 1): in adults, to improve exercise ability and to decrease clinical worsening, and, separately, in pediatric patients aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension. The label carries a boxed warning about two risks: the label says elevations of liver aminotransferases and liver failure have been reported, and that the medicine may cause fetal harm if used during pregnancy. The fetal risk concerns the unborn child and is recorded separately.
Also called TRACLEER
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 75207 (RxNorm also holds 498193, bosentan monohydrate, which has no RxClass classes); UNII Q326023R30; MeSH D000077300 is Bosentan (identity only: the descriptor carries no scope note). RxClass lists the FDA established pharmacologic class Endothelin Receptor Antagonist, so the record is filed under the class page. The label read is the Actelion Pharmaceuticals US, Inc. label for Tracleer, applications NDA021290 (approved 2001-11-20 as a new molecular entity in Drugs@FDA) and NDA209279, effective 2025-11-17 in openFDA. The adult and pediatric statements, the liver warning (recipient not stated) and the fetal warning (recipient: fetal) sit in separate claims and contexts. This page records label indications, the boxed-warning wording named, the mechanism sentence and the class only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label says bosentan is a specific and competitive antagonist at endothelin receptor types ET A and ET B.
Claims and evidence
Context Adults with pulmonary arterial hypertension, as described in the US label of Tracleer
- Recipient
- Adult
- Population
- Adults with pulmonary arterial hypertension (WHO Group 1), as the label states.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Adults, as the label states
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Adults with pulmonary arterial hypertension (WHO Group 1), as the label states.
- Excluded
- None stated
The US label of Tracleer (bosentan tablets and tablets for oral suspension, Actelion Pharmaceuticals US, Inc., applications NDA021290 and NDA209279; the version dated 2025-11-17 in openFDA) describes bosentan as an endothelin receptor antagonist. It lists treating pulmonary arterial hypertension (WHO Group 1) in adults to improve exercise ability and to decrease clinical worsening.
Applies to Adult Adults with pulmonary arterial hypertension, as described in the US label of Tracleer
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. The label also lists a pediatric use, which sits in a separate claim.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA021290.
- Retrieved
- Source effective date
- 2025-11-17
- Source state
- Current
- Version fingerprint
fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20251117.
- Retrieved
- Source effective date
- 2025-11-17
- Source state
- Current
- Version fingerprint
fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (Q-K29-TRA-LB-04, Q-K29-TRA-LB-05).
- Retrieved
- Source effective date
- 2025-11-17
- Source state
- Current
- Version fingerprint
fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context Patients taking bosentan, as described in the hepatotoxicity part of a US label boxed warning
- Recipient
- Recipient not specified
- Population
- Patients who take the medicine, as the label boxed warning describes the liver risk. The passage read gives no age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the passage read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Patients who take the medicine, as the label boxed warning describes the liver risk. The passage read gives no age range.
- Excluded
- None stated
The same US label of Tracleer carries a boxed warning titled risks of hepatotoxicity and embryo-fetal toxicity. For the liver, it says elevations of liver aminotransferases and liver failure have been reported with the medicine.
Applies to Recipient not specified Patients taking bosentan, as described in the hepatotoxicity part of a US label boxed warning
- Certainty method
- Not assessed
- Limitations
- This claim records the boxed-warning statement named above only. The warning also says the medicine is available only through a restricted program and gives monitoring instructions; those instructions are not repeated here. The embryo-fetal part of the warning is in a separate claim about the fetus. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA021290.
- Retrieved
- Source effective date
- 2025-11-17
- Source state
- Current
- Version fingerprint
fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20251117.
- Retrieved
- Source effective date
- 2025-11-17
- Source state
- Current
- Version fingerprint
fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], title
- How it applies
- Label passage quoted in the research quote table (Q-K29-TRA-LB-07).
- Retrieved
- Source effective date
- 2025-11-17
- Source state
- Current
- Version fingerprint
fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], highlights text
- How it applies
- Label passage quoted in the research quote table (Q-K29-TRA-LB-08).
- Retrieved
- Source effective date
- 2025-11-17
- Source state
- Current
- Version fingerprint
fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context Pediatric patients aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension, as described in the US label of Tracleer
- Recipient
- Child
- Population
- Pediatric patients aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension, as the label states.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Pediatric patients aged 3 years and older, as the label states
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Pediatric patients aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension, as the label states.
- Excluded
- None stated
The same US label of Tracleer separately lists treating pulmonary arterial hypertension in pediatric patients aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension, to improve pulmonary vascular resistance.
Applies to Child Pediatric patients aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension, as described in the US label of Tracleer
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. The adult use is in a separate claim. The label's own sentence that the improvement in pulmonary vascular resistance is expected to result in better exercise ability was not recorded.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA021290.
- Retrieved
- Source effective date
- 2025-11-17
- Source state
- Current
- Version fingerprint
fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20251117.
- Retrieved
- Source effective date
- 2025-11-17
- Source state
- Current
- Version fingerprint
fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (Q-K29-TRA-LB-06).
- Retrieved
- Source effective date
- 2025-11-17
- Source state
- Current
- Version fingerprint
fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context The developing fetus, for a person taking bosentan during pregnancy, as described in a US label boxed warning
- Recipient
- Fetal
- Population
- The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Fetus during pregnancy; the passage read gives no gestational ages
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.
- Excluded
- None stated
The same US label of Tracleer carries, within the same boxed warning, a statement that, based on animal data, the medicine may cause fetal harm if used during pregnancy.
Applies to Fetal The developing fetus, for a person taking bosentan during pregnancy, as described in a US label boxed warning
- Certainty method
- Not assessed
- Limitations
- This claim records the boxed-warning statement named above only. The warning also tells prescribers what to do before and during treatment of people who could become pregnant; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA021290.
- Retrieved
- Source effective date
- 2025-11-17
- Source state
- Current
- Version fingerprint
fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20251117.
- Retrieved
- Source effective date
- 2025-11-17
- Source state
- Current
- Version fingerprint
fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], title
- How it applies
- Label passage quoted in the research quote table (Q-K29-TRA-LB-07).
- Retrieved
- Source effective date
- 2025-11-17
- Source state
- Current
- Version fingerprint
fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], highlights text
- How it applies
- Label passage quoted in the research quote table (Q-K29-TRA-LB-09).
- Retrieved
- Source effective date
- 2025-11-17
- Source state
- Current
- Version fingerprint
fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Pregnancy, lactation and children
The claims about this drug whose clinical context is a pregnancy, breastfeeding or a newborn, infant or child, grouped by that context. Each claim is also in Claims and evidence. A group with no claim is not shown, and an empty group does not mean the medicine is safe or unsafe there.
In pregnancy 1
The same US label of Tracleer carries, within the same boxed warning, a statement that, based on animal data, the medicine may cause fetal harm if used during pregnancy.
Applies to Fetal The developing fetus, for a person taking bosentan during pregnancy, as described in a US label boxed warning
Population, setting and follow-up
- The developing fetus when a pregnant person takes the medicine, as the label boxed warning describes the risk. The warning is not about the person who takes the medicine.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Fetus during pregnancy; the passage read gives no gestational ages
- Gestational age Not reported
- Postnatal age Not reported
- Certainty method
- Not assessed
- Limitations
- This claim records the boxed-warning statement named above only. The warning also tells prescribers what to do before and during treatment of people who could become pregnant; that instruction is not repeated here. Other warnings, contraindications and interactions of the label were not recorded, and no pregnancy or lactation guidance is given. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA021290.
- Retrieved
- Source effective date
- 2025-11-17
- Source state
- Current
- Version fingerprint
fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20251117.
- Retrieved
- Source effective date
- 2025-11-17
- Source state
- Current
- Version fingerprint
fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], title
- How it applies
- Label passage quoted in the research quote table (Q-K29-TRA-LB-07).
- Retrieved
- Source effective date
- 2025-11-17
- Source state
- Current
- Version fingerprint
fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], highlights text
- How it applies
- Label passage quoted in the research quote table (Q-K29-TRA-LB-09).
- Retrieved
- Source effective date
- 2025-11-17
- Source state
- Current
- Version fingerprint
fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
In newborns, infants and children 1
The same US label of Tracleer separately lists treating pulmonary arterial hypertension in pediatric patients aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension, to improve pulmonary vascular resistance.
Applies to Child Pediatric patients aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension, as described in the US label of Tracleer
Population, setting and follow-up
- Pediatric patients aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension, as the label states.
- Prescription medicine, as described in the US label
- United States (label of the US Food and Drug Administration)
- Pediatric patients aged 3 years and older, as the label states
- Gestational age Not reported
- Postnatal age Not reported
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. The adult use is in a separate claim. The label's own sentence that the improvement in pulmonary vascular resistance is expected to result in better exercise ability was not recorded.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, NDA021290.
- Retrieved
- Source effective date
- 2025-11-17
- Source state
- Current
- Version fingerprint
fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20251117.
- Retrieved
- Source effective date
- 2025-11-17
- Source state
- Current
- Version fingerprint
fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (Q-K29-TRA-LB-06).
- Retrieved
- Source effective date
- 2025-11-17
- Source state
- Current
- Version fingerprint
fb77b8c5e25ac106f5ffc72c5696b99193482073f339fc4e4e9a52bd0d55c3b4- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists pulmonary arterial hypertension (WHO Group 1) in adults, to improve exercise ability and to decrease clinical worsening, as an indication: Pulmonary arterial hypertension
Applies to Adult Adults with pulmonary arterial hypertension, as described in the US label of Tracleer
The US label of Tracleer (bosentan tablets and tablets for oral suspension, Actelion Pharmaceuticals US, Inc., applications NDA021290 and NDA209279; the version dated 2025-11-17 in openFDA) describes bosentan as an endothelin receptor antagonist. It lists treating pulmonary arterial hypertension (WHO Group 1) in adults to improve exercise ability and to decrease clinical worsening.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. The label also lists a pediatric use, which sits in a separate claim.
-
Claim, not a settled fact FDA label separately lists pulmonary arterial hypertension in pediatric patients aged 3 years and older with idiopathic or congenital disease as an indication: Pulmonary arterial hypertension
Applies to Child Pediatric patients aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension, as described in the US label of Tracleer
The same US label of Tracleer separately lists treating pulmonary arterial hypertension in pediatric patients aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension, to improve pulmonary vascular resistance.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Contraindications, other warnings, interactions and dosing were not recorded. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. The adult use is in a separate claim. The label's own sentence that the improvement in pulmonary vascular resistance is expected to result in better exercise ability was not recorded.
Record details
- Record id
cardio:bosentan- Content hash
208635f46665896361bd27b1336fe1ba6f830a80f7697e65814d7a685e7960f2